Recent Treatment Strategies and Molecular Pathways in Resistance Mechanisms of Antiangiogenic Therapies in Glioblastoma

Cancers, Journal Year: 2024, Volume and Issue: 16(17), P. 2975 - 2975

Published: Aug. 27, 2024

Malignant gliomas present great difficulties in treatment, with little change over the past 30 years median survival time of 15 months. Current treatment options include surgery, radiotherapy (RT), and chemotherapy. New therapies aimed at suppressing formation new vasculature (antiangiogenic treatments) or destroying formed tumor (vascular disrupting agents) show promise. This study summarizes existing knowledge regarding processes by which glioblastoma (GBM) tumors acquire resistance to antiangiogenic treatments. The discussion encompasses activation redundant proangiogenic pathways, heightened cell invasion metastasis, induced hypoxia, creation vascular mimicry channels, regulation immune microenvironment. Subsequently, we explore potential strategies overcome this resistance, such as combining other methods, personalizing treatments for each patient, focusing on therapeutic targets, incorporating immunotherapy, utilizing drug delivery systems based nanoparticles. Additionally, would like discuss limitations methods future directions enhance beneficial effects patients GBM. Therefore, review aims research outcome GBM provide a more promising opportunity thoroughly exploring mechanisms investigating novel strategies.

Language: Английский

---

Unravelling exosome paradigm: Therapeutic, diagnostic and theranostics application and regulatory consideration

Life Sciences, Journal Year: 2025, Volume and Issue: unknown, P. 123472 - 123472

Published: Feb. 1, 2025

Language: Английский

---

Molecular insights to therapeutic in cancer: role of exosomes in tumor microenvironment, metastatic progression and drug resistance

Drug Discovery Today, Journal Year: 2024, Volume and Issue: 29(8), P. 104061 - 104061

Published: June 18, 2024

Language: Английский

---

Exploring the role of transcription factor TWIST1 in bladder cancer progression

Cancer Genetics, Journal Year: 2025, Volume and Issue: 292-293, P. 44 - 48

Published: Jan. 21, 2025

Language: Английский

---

SMYD3 plays a pivotal role in mediating the epithelial-mesenchymal transition process in breast cancer

Biochemical and Biophysical Research Communications, Journal Year: 2025, Volume and Issue: 749, P. 151363 - 151363

Published: Jan. 22, 2025

Language: Английский

---

Tiny messengers, big Impact: Exosomes driving EMT in oral cancer

Pathology - Research and Practice, Journal Year: 2025, Volume and Issue: 268, P. 155873 - 155873

Published: Feb. 27, 2025

Language: Английский

---

Exosomes: A Promising Drug Delivery Tool in Hepatic Drug Delivery

Journal of Drug Delivery Science and Technology, Journal Year: 2025, Volume and Issue: unknown, P. 106761 - 106761

Published: March 1, 2025

Language: Английский

---

The Role of Hypoxia-Inducible Factor-1α (HIF-1α) in the Progression of Ovarian Cancer: Perspectives on Female Infertility

Cells, Journal Year: 2025, Volume and Issue: 14(6), P. 437 - 437

Published: March 14, 2025

Hypoxia-Inducible Factor-1α (HIF-1α) is crucial in the progression of ovarian cancer, especially influencing its tumor microenvironment and promoting pathogenic pathways that worsen female infertility. In hypoxic settings, HIF-1α stabilized activates transcription genes associated with angiogenesis, metabolic reprogramming, epithelial-to-mesenchymal transition, therapeutic resistance. Angiogenesis glycolytic reprogramming mediated by HIF-1 proliferation, survival, metastasis. Its dysfunction concurrently impairs homeostasis, undermining follicular growth, hormone synthesis, vascular network, consequently contributing to Moreover, induces persistent inflammation oxidative stress, an environment damaging reproductive health. Due dual function cancer growth infertility, a potential target. Strategies including small molecule inhibitors nanoparticle-mediated delivery drugs possess reduce activity, hence reducing while protecting fertility. This review seeks clarify molecular basis effects on providing insights into novel treatment approaches target both controlling disease preserving

Language: Английский

---

Docetaxel‐Encapsulated Catalytic Pt/Au Nanotubes for Synergistic Chemo‐Photothermal Therapy of Triple‐Negative Breast Cancer

Advanced Healthcare Materials, Journal Year: 2024, Volume and Issue: 13(29)

Published: Aug. 27, 2024

The combination of photothermal therapy with chemotherapy has emerged as a promising therapeutic modality for addressing triple-negative breast cancer (TNBC). This manuscript describes novel hybrid nanoplatform comprising ultrathin catalytic platinum/gold (Pt/Au) nanotubes encapsulated docetaxel and phase-change materials (PCMs) the photoacoustic imaging-guided synergistic chemo-photothermal TNBC. Upon irradiation near-infrared laser, heating converts solid-state PCM into liquid, triggering controlled release docetaxel. thin Pt layer within enhances nanotube's thermal stability, thus prolonging ablation tumors. Furthermore, platinum effectively mitigates tumor hypoxia by catalyzing decomposition hydrogen peroxides to generate oxygen in microenvironment, improving efficiency chemotherapy. It is demonstrated that drug-loaded achieve significant inhibition rates 75.4% vivo on 4T1 tumor-bearing mice, significantly surpassing control groups. These also notably extend survival, attributable effects prolonged facilitated oxygenation-enhanced leverages unique properties Pt/Au NTs-DTX/PCM nanoplatform, optimizing outcomes. envisioned this may find important applications managing superficial malignant solid tumors general.

Language: Английский

---

Immunological challenges and opportunities in glioblastoma multiforme: A comprehensive view from immune system lens

Life Sciences, Journal Year: 2024, Volume and Issue: 357, P. 123089 - 123089

Published: Oct. 1, 2024

Language: Английский

---